Skip to main content

Pembrolizumab is the first immune checkpoint inhibitor to receive approval for head and neck cancer

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
Pembrolizumab is the first immune checkpoint inhibitor to receive approval for head and neck cancer

User login

Username

Password

Reset your password

Type	Lead	score